TELA Bio Announces $17M Annual Expense Reduction Through 20% Workforce Streamlining and Resource Optimization, Extending Cash Runway Into 2028
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief
TELA Bio is cutting costs by laying off some workers and spending less money, which means their cash will last longer before they need more. When a company does this, watch whether they can still make and sell their products well—cost-cutting helps, but the real question is if customers still want what they make.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.